CNS Lymphoma Diagnosis and Treatment
CNS Lymphoma Diagnosis and Treatment is a research topic within Neurology. Science Explorer counts 17k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the diagnosis, treatment, and management of primary central nervous system lymphoma (PCNSL). It covers various aspects such as prognostic scoring systems, chemotherapy and radiotherapy regimens, use of methotrexate and rituximab therapy, genetic features, neurological masquerade syndromes, and cognitive functions in PCNSL patients.
- Primary CNS Lymphoma
- Prognostic Scoring System
- Chemotherapy
- Radiotherapy
- Methotrexate
- Intravascular Lymphoma
- Rituximab Therapy
- Genetic Features
- Neurological Masquerade Syndromes
- Cognitive Functions
- Research works
- 17k fractional, since 1950
- In the world top 10%
- 1.7k per year above
- Top-10% rate
- 10.3% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- +18% the tick is no change
- Largest producer
United States
34% of the 10 largest, 2022-now
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead CNS Lymphoma Diagnosis and Treatment research?
By volume, the United States and China publish the most (1k and 700 works in 2022-now).
By volume, 2022-now
- 1
United States 1k works
- 2
China 700 works
- 3
Japan 324 works
- 4
India 190 works
- 5
Germany 158 works
- 6
France 147 works
- 7
Italy 134 works
- 8
United Kingdom 100 works
- 9
Türkiye 92 works
- 10
Spain 91 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead CNS Lymphoma Diagnosis and Treatment research?
By volume in 2022-now, Capital Medical University publishes the most CNS Lymphoma Diagnosis and Treatment research, followed by Mayo Clinic and Harvard University.
By volume, 2022-now
- 1
Capital Medical University
China 56 works
- 2
Mayo Clinic
United States 47 works
- 3
Harvard University
United States 34 works
- 4
The University of Texas MD Anderson Cancer Center
United States 33 works
- 5
Chinese Academy of Medical Sciences & Peking Union Medical College
China 30 works
- 6
Memorial Sloan Kettering Cancer Center
United States 28 works
- 7
Fudan University
China 26 works
- 8
Sichuan University
China 25 works
- 9
Shanghai Jiao Tong University
China 23 works
- 10
Sun Yat-sen University
China 23 works
Who are the leading researchers in CNS Lymphoma Diagnosis and Treatment?
The most-cited researchers publishing on CNS Lymphoma Diagnosis and Treatment include Robert John Tibshirani, Gad A. Getz and Jost Bruno Jonas.
- 1
Robert John Tibshirani
United States 396k citations
- 2
Gad A. Getz
United States 364k citations
- 3
Jost Bruno Jonas
Germany 350k citations
- 4
Matthias Egger
Switzerland 326k citations
- 5
Hagop M. Kantarjian
United States 273k citations
- 6
Carlo La Vecchia
Italy 258k citations
- 7
Kaj Blennow
Sweden 247k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is CNS Lymphoma Diagnosis and Treatment research done?
The largest centres of CNS Lymphoma Diagnosis and Treatment research in 2022-now are Beijing (China), Tokyo (Japan), New York (United States) and Shanghai (China).
Largest cities, 2022-now
- 1
Beijing
China 147 works
- 2
Tokyo
Japan 74 works
- 3
New York
United States 67 works
- 4
Shanghai
China 65 works
- 5
Paris
France 60 works
- 6
Houston
United States 46 works
- 7
Seoul
South Korea 42 works
- 8
Guangzhou
China 39 works
- 9
London
United Kingdom 38 works
- 10
Philadelphia
United States 36 works
Where is the best place to study CNS Lymphoma Diagnosis and Treatment?
Among universities, judged by research, Capital Medical University, Harvard University and University of Toronto score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.
Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in CNS Lymphoma Diagnosis and Treatment, country by countryIs CNS Lymphoma Diagnosis and Treatment research growing?
Output in 2022-2025 was 18% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are CNS Lymphoma Diagnosis and Treatment.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is CNS Lymphoma Diagnosis and Treatment as a percentage of every work published that year, 0.014% in 2024.
Fractional works of CNS Lymphoma Diagnosis and Treatment over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Discussion
Ask a question or share a note about CNS Lymphoma Diagnosis and Treatment. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.